Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0000950170-24-139789
Filing Date
2024-12-23
Accepted
2024-12-23 18:31:30
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 7055
  Complete submission text file 0000950170-24-139789.txt   8520
Mailing Address C/O REXAHN PHARMACEUTICALS, INC. 15245 SHADY GROVE ROAD, SUITE 455 ROCKVILLE MD 20850
Business Address
Sullivan Lara (Filed by) CIK: 0001769457 (see all company filings)

Type: SCHEDULE 13D/A

Mailing Address 321 HARRISON AVENUE BOSTON MA 02118
Business Address 321 HARRISON AVENUE BOSTON MA 02118 (617) 221-9059
Pyxis Oncology, Inc. (Subject) CIK: 0001782223 (see all company filings)

EIN.: 831160910 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-92951 | Film No.: 241575213
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)